⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 2024ClinicoEconomics and Outcomes Research

Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada

Nigel S. B. Rawson David J. Stewart

View at Publisher

Ask AI

Bookmark

Share

Abstract

To evaluate whether time targets for Canadian Agency for Drugs and Technologies in Health (CADTH) reimbursement reviews and pan-Canadian Pharmaceutical Alliance (pCPA) price negotiations are being achieved for oncology drugs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rawson et al. (2024) studied this question.

synapsesocial.com/papers/68e6c1b7b6db6435876407de https://doi.org/10.2147/ceor.s462872

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses2024 · 2 citations
2Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement2024 · 12 citations
3Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement2024 · 2 citations
4Is Canada Moving towards a More Agile Regulatory Approval and a Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?2024 · 1 citations
5Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?2024 · 7 citations

More related papers

Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action2024
Editorial: Volume 2: real world evidence (RWE): paths to enhancing patient access to new medications2026
Health technology assessment reports for oncology medications in Canada from 2018 to 2025: methodological critiques on manufacturers’ submissions and a comparison between manufacturers and Canada’s drug agency (CDA) analyses2026

More from ClinicoEconomics and Outcomes Research

Economic Burden of treated Lower-Risk Myelodysplastic Syndromes in France: A Population-Based StudyThu,
Cost-Effectiveness and Budget Impact of Cardioform versus Amplatzer and Medical Therapy Alone for Patent Foramen Ovale Closure: A UK Payer PerspectiveTue,